-
-
-
-
-
-
-
ARS Pharmaceuticals (SPRY) Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis
-
-
-
-
66,432 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

